TY - JOUR
T1 - Novel therapies for chronic myelogenous leukemia
AU - Jahagirdar, Balkrishna N.
AU - Miller, Jeffrey S.
AU - Shet, Arun
AU - Verfaillie, Catherine M.
PY - 2001/5
Y1 - 2001/5
N2 - The BCR-ABL oncogene is essential to the pathogenesis of chronic myelogenous leukemia, and immune mechanisms play an important role in control of this disease. Understanding of the molecular pathogenesis of chronic myelogenous leukemia has led to the development of several novel therapies, which can be broadly divided into therapies based on 1) inhibition of the BCR-ABL oncogene expression, 2) inhibition of other genes important to the pathogenesis of chronic myelogenous leukemia, 3) inhibition of BCR-ABL protein function, and 4) immunomodulation. We have systematically reviewed each of these novel therapeutic approaches in this article.
AB - The BCR-ABL oncogene is essential to the pathogenesis of chronic myelogenous leukemia, and immune mechanisms play an important role in control of this disease. Understanding of the molecular pathogenesis of chronic myelogenous leukemia has led to the development of several novel therapies, which can be broadly divided into therapies based on 1) inhibition of the BCR-ABL oncogene expression, 2) inhibition of other genes important to the pathogenesis of chronic myelogenous leukemia, 3) inhibition of BCR-ABL protein function, and 4) immunomodulation. We have systematically reviewed each of these novel therapeutic approaches in this article.
UR - http://www.scopus.com/inward/record.url?scp=0034995997&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0034995997&partnerID=8YFLogxK
U2 - 10.1016/S0301-472X(01)00633-6
DO - 10.1016/S0301-472X(01)00633-6
M3 - Review article
C2 - 11376866
AN - SCOPUS:0034995997
SN - 0301-472X
VL - 29
SP - 543
EP - 556
JO - Experimental Hematology
JF - Experimental Hematology
IS - 5
ER -
